JP2013537539A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537539A5
JP2013537539A5 JP2013524239A JP2013524239A JP2013537539A5 JP 2013537539 A5 JP2013537539 A5 JP 2013537539A5 JP 2013524239 A JP2013524239 A JP 2013524239A JP 2013524239 A JP2013524239 A JP 2013524239A JP 2013537539 A5 JP2013537539 A5 JP 2013537539A5
Authority
JP
Japan
Prior art keywords
antibody
medicament according
binds
monoclonal antibody
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013524239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/047532 external-priority patent/WO2012021773A1/en
Publication of JP2013537539A publication Critical patent/JP2013537539A/ja
Publication of JP2013537539A5 publication Critical patent/JP2013537539A5/ja
Pending legal-status Critical Current

Links

JP2013524239A 2010-08-13 2011-08-12 疾患の治療のためのIL−1β及びIL−18に対する抗体 Pending JP2013537539A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37376010P 2010-08-13 2010-08-13
US61/373,760 2010-08-13
PCT/US2011/047532 WO2012021773A1 (en) 2010-08-13 2011-08-12 Antibodies to il-1beta and il-18, for treatment of disease

Publications (2)

Publication Number Publication Date
JP2013537539A JP2013537539A (ja) 2013-10-03
JP2013537539A5 true JP2013537539A5 (OSRAM) 2014-10-09

Family

ID=44511598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524239A Pending JP2013537539A (ja) 2010-08-13 2011-08-12 疾患の治療のためのIL−1β及びIL−18に対する抗体

Country Status (9)

Country Link
EP (1) EP2603525A1 (OSRAM)
JP (1) JP2013537539A (OSRAM)
KR (1) KR20130100125A (OSRAM)
CN (2) CN103154032A (OSRAM)
BR (1) BR112013003279A2 (OSRAM)
CA (1) CA2808185A1 (OSRAM)
MX (1) MX2013001267A (OSRAM)
RU (1) RU2013110844A (OSRAM)
WO (1) WO2012021773A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707235B1 (en) * 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
HUE044954T2 (hu) 2013-03-14 2019-11-28 Univ Laval Elektroretinográfiás (ERG) rendszer pszichiátriai rendellenességek felmérésére
KR20160005044A (ko) * 2013-05-17 2016-01-13 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
CN103554264B (zh) * 2013-11-05 2015-08-12 哈尔滨博翱生物医药技术开发有限公司 针对IL-1β和IL-17A的双特异性抗体及其应用
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
WO2016075034A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
GB201815045D0 (en) * 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN110251657B (zh) * 2019-06-14 2020-11-17 中山大学 Ebv brlf1及其功能性小肽在抑制炎症小体活性中的应用
JP2023519581A (ja) 2020-03-26 2023-05-11 ディアメンティス・インコーポレイテッド 網膜信号データを処理し、状態を識別するためのシステムおよび方法
TW202233237A (zh) * 2020-11-18 2022-09-01 瑞士商諾華公司 用於在治療nlrc4-gof炎性體病變中使用的雙特異性抗體
TW202306989A (zh) * 2021-06-22 2023-02-16 瑞士商諾華公司 用於在治療化膿性汗腺炎中使用的雙特異性抗體

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577300A (en) 1897-02-16 Printing-press
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010989A (en) 1975-10-14 1977-03-08 American Hospital Supply Corporation Lockable drawer compartment
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
ATE113846T1 (de) 1988-06-21 1994-11-15 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ATE233813T1 (de) 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク,インコーポレイテッド 二特異的免疫アドヘジン
JPH08500826A (ja) 1992-08-21 1996-01-30 ジェネンテク,インコーポレイテッド Lfa−1仲介疾患を処置する方法
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
DE69405251T2 (de) 1993-12-10 1998-02-05 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
MX9603773A (es) 1994-03-03 1997-07-31 Genentech Inc Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios.
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE122004000047I1 (de) 1996-11-27 2005-04-21 Genentech Inc Humanisierte anti-koerper gegen cd11a.
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001040309A2 (en) 1999-10-29 2001-06-07 Genentech, Inc. Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
UA94022C2 (ru) * 2000-02-21 2011-04-11 Апплайд Резеч Системз Арс Холдинг Н.В. Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
JP4955185B2 (ja) * 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
EP2845864A3 (en) 2001-05-11 2015-06-10 Amgen, Inc Peptides and related molecules that bind to TALL - 1
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090298764A1 (en) * 2006-03-15 2009-12-03 Regents Of The University Of Colorado Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases
EP2021026A1 (en) * 2006-04-14 2009-02-11 Novartis AG Use of il-i antibodies for treating ophthalmic disorders
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
KR20160017119A (ko) * 2007-05-29 2016-02-15 노파르티스 아게 항-il-1-베타 치료법에 대한 신규 적응증
WO2009099545A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
WO2010028275A1 (en) * 2008-09-05 2010-03-11 Xoma Technology Ltd. METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES

Similar Documents

Publication Publication Date Title
JP2013537539A5 (OSRAM)
AlGhamdi et al. Treatment of generalized vitiligo with anti-TNF-a agents
JP2014533279A5 (OSRAM)
BR112014022812A2 (pt) anticorpos anti-cd27 humanos, métodos e usos
HRP20250472T1 (hr) Režim doziranja antitijela anti-alpha4beta7
JP2013501814A5 (OSRAM)
RU2013110844A (ru) АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
JP2014513722A5 (OSRAM)
JP2009539841A5 (OSRAM)
JP2014530226A5 (OSRAM)
JP2016500251A5 (OSRAM)
NZ629178A (en) Antibodies to matrix metalloproteinase 9
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
IL225310A (en) Use of antibody 17-il to prepare a drug for the treatment of adjunct
JP2013538796A5 (OSRAM)
JP2020510039A5 (OSRAM)
RU2017120361A (ru) Антитела к pdgf-b и способы их применения
JP2016509585A5 (OSRAM)
FI3452513T3 (fi) Humanisoituja anti-il-1r3-vasta-aineita
Zeng et al. Antibody therapies in autoimmune inflammatory myopathies: promising treatment options
FI3687567T3 (fi) Adrenomedulliinin (adm) vasta-ainetta sitova aine käytettäväksi sairauden oireiden hoidossa tai ehkäisyssä
JP2017520562A5 (OSRAM)
MX345019B (es) Nuevo anticuerpo ctgf antihumano.
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
Lamot et al. The'head-to-head'comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis